Nice | Ticagrelor for the treatment of acute coronary syndrome ACS

4th November 2011 by Louise Hudman

Ticagrelor is a PO drug which inhibits platelet aggregation. In combination with aspirin it is more effective than clopidogrel + aspirin at reducing the endpoint of MI or death from vascular events.

It will be started by secondary care and continued by cardiologists, so we shouldn’t really have to initiate it.

It will be started in patients who’ve had a STEMI where primary percutaneous coronary intervention (PCI) is considered and also in patients with a NSTEMI who have certain other risk factors.

Read more

No credit card details needed – it takes two minutes.

Join free trial

Login

Already a member? Login to view this content.

Login

"I have been a member of the NASGP for about 18 months and find the support and advice invaluable.

It was especially helpful when I started locum work. I think I must have spent hours on the website devouring every single article as I was keen to learn all I could before I went solo. "

Dr Sally Watkins

Dr Sally Watkins

See the full list of features within our NASGP membership plans

Membership